Recruiting

SFBT-C

Sponsor:

University of Michigan Rogel Cancer Center

Code:

NCT06941324

Conditions

Hematopoietic and Lymphatic System Neoplasm

Malignant Solid Neoplasm

Eligibility Criteria

Sex: All

Age: 15 - 39

Healthy Volunteers: Not accepted

Interventions

Behavioral Intervention

Best Practice

Communication Intervention

Discussion

Health Promotion and Education

Study Details

Brief summary:

This clinical trial evaluates the how well a virtually delivered solution-focused brief therapy (SFBT-C) works to decrease adolescent and young adult cancer survivors' psychological distress in comparison to enhanced treatment-as-usual care. Cancer and its treatment can have immediate and long-term impacts on adolescent and young adult cancer survivor's lives, including education and employment, financial stability, sexual health, and social, romantic, and family relationships. Consequently, many adolescent and young adult cancer survivors report psychological distress, often manifesting as depression and anxiety, and may benefit from psychotherapy to improve their engagement with medical treatment and overall quality of life. SFBT-C is a theory-driven and brief hope-based psychotherapy designed for the unique psychosocial needs facing adolescent and young adult cancer survivors. Undergoing SFBT-C may work better than treatment-as-usual care for the support of psychological distress in adolescent and young adult cancer survivors.

Conditions

Hematopoietic and Lymphatic System Neoplasm

Malignant Solid Neoplasm

Study ID

NCT06941324

Start date

Jun 23, 2025

Status verified date

Jul, 2026

Completion date

Jul 1, 2028

Anticipated

Primary completion date

Jul 1, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 15 - 39

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • 15 - 39 years old
  • Diagnosed with cancer
  • Receiving active cancer care (6 weeks post initial diagnosis to control for emotional responses to normative stressors) or within 5 years of post-treatment survivorship
  • Experiencing psychological distress (i.e., a t-score >= 57 on the Brief Symptom Inventory - 18 items \[BSI-18\])
  • Fluent in English

Exclusion Criteria:

  • End-of-life care
  • > 5 years into the post-treatment survivorship
  • Major physical challenges (e.g., hearing loss, developmental delay)
  • Acute mental health conditions (e.g., active psychosis, suicide risk)
  • Receiving or newly initiated psychotherapy for psychological distress during the study period

Study Design

Enrollment

60 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

active comparator: Supportive Care (eTAU)

Patients receive eTAU and receive an educational book to address emotional challenges associated with cancer and strategies and resources to address these challenges over 4-8 weeks on study. Additionally, patients receive check in calls from clinicians QW to answer any questions patients may have about the book.

experimental: Supportive Care (SFBT-C)

Patients undergo virtual SFBT sessions over 30 minutes each QW over 4-8 weeks on study. Patients also receive an educational manual and participate in discussions after each session on study.

Interventions

Behavioral Intervention

Undergo SFBT-C

Best Practice

Receive eTAU

Communication Intervention

Receive check in calls from clinician

Discussion

Participate in discussions

Health Promotion and Education

Receive educational manual

Health Promotion and Education

Receive educational book

Interview

Ancillary studies

Questionnaire Administration

Ancillary studies

Primary outcome measure

  • Efficacy of solution-focused brief therapy in cancer survivors (SFBT-C) [ Time Frame: At baseline, immediate post-intervention, and 4 and 8 weeks post-intervention ]

Central Contacts and Locations

Central contacts

Cancer AnswerLine

1-800-865-1125CancerAnswerLine@med.umich.edu

Locations

University of Michigan Comprehensive Cancer Center

Recruiting

Ann Arbor, Michigan, United States, 48109

Contacts

Cancer AnswerLine

800-865-1125CancerAnswerLine@med.umich.edu

Principal Investigator:

Sunnye Mayes

More Information

Sponsor

University of Michigan Rogel Cancer Center

Last update posted

Jul 16, 2026

Last verified

Jul, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Michigan Rogel Cancer Center on 2026-07-16.